

Tularaemia (Rabbit Fever) Drug Development Pipeline Study, H2 2018

<https://marketpublishers.com/r/T2775866EF4EN.html>

Date: August 2018

Pages: 35

Price: US\$ 1,200.00 (Single User License)

ID: T2775866EF4EN

Abstracts

Tularaemia (Rabbit Fever) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Tularaemia (Rabbit Fever) pipeline products.

DISEASE OVERVIEW

Tularaemia or *Francisella tularensis* infection or Rabbit Fever is a catastrophic disease in times of outbreaks as it leads to deaths in large numbers. It is spread through skin contact with animals, fly bites, contaminated water etc. Skin ulcers, broadened lymph nodes and fever are typical symptoms of the Tualaemia disease.

The disease causing organism%li%*Francisella tularensis* lives for long periods (around 30 days) in water and animal carcasses. Based on biochemical and molecular characteristics, these are classified typically as Type A, Type B and others.

However, currently, the prevalence of Tularaemia is low with an estimated 0.7 cases found in 1 million populations in the US. The disease is typically treated for two to three weeks through antibiotics.

Companies currently investing their resources in Tularaemia pipeline include%li%Appili Therapeutics Inc, Aradigm Corporation, Emergent BioSolutions Inc, EpiVax Inc and Tetrphase Pharmaceuticals Inc.

REPORT DESCRIPTION

The Tularaemia (Rabbit Fever) pipeline guide presents complete overview of drugs

currently being developed for Tularaemia (Rabbit Fever). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Tularaemia (Rabbit Fever) pipeline candidate.

Research and Development progress along with latest news related to each of the Tularaemia (Rabbit Fever) pipeline candidates is included.

Major companies participating in therapeutic development of Tularaemia (Rabbit Fever) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Tularaemia (Rabbit Fever) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Tularaemia (Rabbit Fever) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Tularaemia (Rabbit Fever) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF TULARAEMIA (RABBIT FEVER) PIPELINE REPORT INCLUDES

Panorama of Tularaemia (Rabbit Fever) pipeline markets including statistics on therapeutic drugs and companies involved

Tularaemia (Rabbit Fever) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Tularaemia (Rabbit Fever) pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Tularaemia (Rabbit Fever) pipeline with

short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Tularaemia (Rabbit Fever) pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Tularaemia (Rabbit Fever) pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Tularaemia (Rabbit Fever) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Tularaemia Pipeline include-
 - Number of Companies with Tularaemia projects in pre-clinical Development-
 - Number of Companies with Tularaemia projects in Clinical Development-
 - Tularaemia Pipeline Companies based in Americas
 - Tularaemia Pipeline Companies based in Europe
 - Tularaemia Pipeline Companies based in Asia Pacific
 - Tularaemia Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
 - Tularaemia Pipeline Agents in pre- clinical/Discovery stage of Development
 - Tularaemia Pipeline Agents in Clinical Development stage
 - Tularaemia Pipeline Therapeutic Compounds received special status
 - Mechanism of Action of most pipeline Drugs-
 - Small molecules among the Tularaemia Pipeline agents

II. INSIGHTS INTO TULARAEMIA PIPELINE

1. Disease Overview
 - Introduction to Tularaemia
 - Symptoms and Causes of Tularaemia
 - Treatment or Prevention Options for Tularaemia
 - Other Details
2. Phase wise Pipeline Compounds
 - Tularaemia Pipeline- Pre- Clinical/Discovery stage Drugs
 - Tularaemia Pipeline- Phase 1 stage Drugs
 - Tularaemia Pipeline- Phase 2 stage Drugs
 - Tularaemia Pipeline- Phase 3 stage Drugs
 - Tularaemia Pipeline- Pre-Registration stage Drugs
3. Company wise Tularaemia Pipeline Compounds
4. Tularaemia Pipeline by Mechanism of Action

III. TULARAEMIA PIPELINE COMPOUND DETAILS

ATI-1701
ciprofloxacin
EV-035

Tularemia Vaccine

TP-271

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. TULARAEMIA PIPELINE COMPANY BRIEFS

Appili Therapeutics Inc

Aradigm Corporation

Emergent BioSolutions Inc

EpiVax Inc

Tetraphase Pharmaceuticals Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL TULARAEMIA PIPELINE MARKET

VI. APPENDIX

1. Publisher's Expertise

2. Research Methodology

3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

I would like to order

Product name: Tularaemia (Rabbit Fever) Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/T2775866EF4EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T2775866EF4EN.html>